GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Debt-to-Revenue

Scinopharm Taiwan (TPE:1789) Debt-to-Revenue : 0.23 (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Scinopharm Taiwan's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was NT$56 Mil. Scinopharm Taiwan's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was NT$622 Mil. Scinopharm Taiwan's annualized Revenue for the quarter that ended in Sep. 2024 was NT$2,897 Mil. Scinopharm Taiwan's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.23.


Scinopharm Taiwan Debt-to-Revenue Historical Data

The historical data trend for Scinopharm Taiwan's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan Debt-to-Revenue Chart

Scinopharm Taiwan Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.19 0.20 0.21 0.20

Scinopharm Taiwan Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.14 0.19 0.22 0.23

Competitive Comparison of Scinopharm Taiwan's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Debt-to-Revenue falls into.



Scinopharm Taiwan Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Scinopharm Taiwan's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(50.872 + 570.231) / 3186.083
=0.19

Scinopharm Taiwan's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(55.593 + 622.136) / 2896.892
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Scinopharm Taiwan Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinopharm Taiwan Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines